Anti-CCR2 monoclonal antibody therapy (MLN1202) has been investigated safely in people with rheumatoid arthritis, where it reduced monocyte counts and free CCR2 on circulating monocytes.47 Here, CCR2 is linked to rheumatoid arthritis.